Evidence map›Paper›PMID 36294544›Full record

ArticleJournal of clinical medicine2022

Prospective Evaluation of Different Methods for Volumetric Analysis on [

Egesta Lopci, Caterina Elia, Barbara Catalfamo, Roberta Burnelli, Valli De Re, Lara Mussolin, Arnoldo Piccardo, Angelina Cistaro, Eugenio Borsatti, Pietro Zucchetta and 8 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. PET scout: A valuable technology in pediatricEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Prognostic value of baseline and interim [European journal of nuclear medicine and molecular imaging · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Egesta LopciNuclear Medicine Unit, IRCCS-Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.
Caterina EliaAYA and Pediatric Radiotherapy Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
Barbara CatalfamoNuclear Medicine Unit, University Hospital "Mater Domini, 88100 Catanzaro, Italy.
Roberta BurnelliPediatric Onco-Hematologic Unit, University Hospital S. Anna, 44121 Ferrara, Italy.ORCID 0000-0002-8437-1954
Valli De ReImmunopathology and Cancer Biomarkers Unit, Department of Translational Research, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.ORCID 0000-0001-6100-9373
Lara MussolinPediatric Hemato-Oncology Clinic, Department of Women's and Children's Health, University of Padua, 35128 Padua, Italy.
Arnoldo PiccardoDepartment of Nuclear Medicine, Galliera Hospital, 16128 Genoa, Italy.ORCID 0000-0002-6779-1471
Angelina CistaroNuclear Medicine Division, Salus Alliance Medical, 16128 Genoa, Italy.ORCID 0000-0001-8024-8425
Eugenio BorsattiNuclear Medicine Department, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
Pietro ZucchettaNuclear Medicine Department, Padova University Hospital, 35128 Padua, Italy.
Maurizio BianchiOnco-Hematology Division, Regina Margherita Hospital, 10126 Torino, Italy.
Salvatore BuffardiDepartment of Oncology, Hospital Santobono-Pausilipon, 80123 Naples, Italy.
Piero FarruggiaDepartment of Pediatric Onco-Hematology, A.R.N.A.S. Ospedali Civico, 90127 Palermo, Italy.ORCID 0000-0002-3412-0399
Alberto GaraventaPediatric Oncology Unit, I RCCS G.Gaslini Hospital, 16147 Genoa, Italy.
Alessandra SalaPediatric Division, Hospital San Gerardo, 20900 Monza, Italy.
Luciana VintiDepartment of Pediatric Hematology and Oncology, Ospedale Bambino Gesù, IRCSS, 00165 Rome, Italy.ORCID 0000-0003-2803-992X
Christine Mauz-KoerholzPädiatrische Hämatologie und Onkologie, Zentrum für Kinderheilkunde der Justus-Liebig-Universität Gießen, 35392 Giessen, Germany.ORCID 0000-0002-8205-8665
Maurizio MascarinAYA and Pediatric Radiotherapy Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.ORCID 0000-0002-2828-0257

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Therapy response evaluation by 18F-fluorodeoxyglucose PET/CT (FDG PET) has become a powerful tool for the discrimination of responders from non-responders in pediatric Hodgkin lymphoma (HL). Recently, volumetric analyses have been regarded as a valuable tool for disease prognostication and biological characterization in cancer. Given the multitude of methods available for volumetric analysis in HL, the AIEOP Hodgkin Lymphoma Study Group has designed a prospective analysis of the Italian cohort enrolled in the EuroNet-PHL-C2 trial. Methods: Primarily, the study aimed to compare the different segmentation techniques used for volumetric assessment in HL patients at baseline (PET1) and during therapy: early (PET2) and late assessment (PET3). Overall, 50 patients and 150 scans were investigated for the current analysis. A dedicated software was used to semi-automatically delineate contours of the lesions by using different threshold methods. More specifically, four methods were applied: (1) fixed 41% threshold of the maximum standardized uptake value (SUVmax) within the respective lymphoma site (V41%), (2) fixed absolute SUV threshold of 2.5 (V2.5); (3) SUVmax(lesion)/SUVmean liver >1.5 (Vliver); (4) adaptive method (AM). All parameters obtained from the different methods were analyzed with respect to response. Results: Among the different methods investigated, the strongest correlation was observed between AM and Vliver (rho > 0.9; p < 0.001 for SUVmean, MTV and TLG at all scan timing), along with V2.5 and AM or Vliver (rho 0.98, p < 0.001 for TLG at baseline; rho > 0.9; p < 0.001 for SUVmean, MTV and TLG at PET2 and PET3, respectively). To determine the best segmentation method, we applied logistic regression and correlated different results with Deauville scores at late evaluation. Logistic regression demonstrated that MTV (metabolic tumor volume) and TLG (total lesion glycolysis) computation according to V2.5 and Vliver significantly correlated to response to treatment (p = 0.01 and 0.04 for MTV and 0.03 and 0.04 for TLG, respectively). SUVmean also resulted in significant correlation as absolute value or variation. Conclusions: The best correlation for volumetric analysis was documented for AM and Vliver, followed by V2.5. The volumetric analyses obtained from V2.5 and Vliver significantly correlated to response to therapy, proving to be preferred thresholds in our pediatric HL cohort.

Indexed as

FDG PETHodgkin’s lymphomainterim evaluationmethod comparisonpediatricresponse assessmentvolumetric analysis

Identifiers

PMID36294544
PMCPMC9605658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.